Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Derivatives -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (216)	5/24/1999 9:09:00 AM
From: LLCF	Read Replies (2) \| Respond to of 555

<Lawsuit Against Genentech > While the GNE options are high by historical standards for GNE, they have always been dirt cheap because of the nature (callable & putable) of their "special" common stock and the Roche option overhanging the upside. That said, this is some big lawsuit and with the prices of the options it's an interesting speculation... I'd (or someone) have to look at the nature of the GNE stock re. the Roche deal in order to recommend a strategy, and not being already familiar, this would take me more time than I am currently willing to spend... anyone else already familiar want to chip in? DAK